Residual risk identified in routine noninvasive follow-up assessments in pulmonary arterial hypertension

被引:2
作者
Ostermann, Jonna [1 ,2 ]
Pott, Julian [1 ,2 ]
Hennigs, Jan K. [1 ,2 ]
Roedl, Kevin [3 ]
Sinning, Christoph [4 ]
Harbaum, Lars [1 ,2 ]
Klose, Hans [1 ,2 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Div Resp Med, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Med 2, Ctr Pulm Arterial Hypertens Hamburg, Hamburg, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Dept Intens Care Med, Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Univ Heart & Vasc Ctr Hamburg, Dept Cardiol, Hamburg, Germany
关键词
PREDICTING SURVIVAL; SCORE CALCULATOR; REGISTRY; RATIO;
D O I
10.1183/23120541.00072-2023
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background The 2022 ESC/ERS guidelines on pulmonary hypertension recommend noninvasive risk assessments based on three clinical variables during follow-up in patients with pulmonary arterial hypertension (PAH). We set out to test whether residual risk can be captured from routinely measured noninvasive clinical variables during follow-up in PAH. Methods We retrospectively studied 298 incident PAH patients from a German pulmonary hypertension centre who underwent routine noninvasive follow-up assessments including exercise testing, echocardiography, electrocardiography, pulmonary function testing and biochemistry. To select variables, we used least absolute shrinkage and selection operator (LASSO)-regularised Cox regression models. Outcome was defined as mortality or lung transplant after first follow-up assessment. Results 12 noninvasive variables that were associated with outcomes in a training sub-cohort (n=208) after correction for multiple testing entered LASSO modelling. A model combining seven variables discriminated 1-year (area under the curve (AUC) 0.83, 95% confidence interval (CI) 0.68-0.99, p=8.4x10(-6)) and 3-year (AUC 0.81, 95% CI 0.70-0.92, p=2.9x10(-8)) outcome status in a replication subcohort (n=90). The model's discriminatory ability was comparable to that of the guideline approach in the replication sub-cohort. From the individual model components, World Health Organization functional class, 6-min walking distance and the tricuspid annular plane systolic excursion to systolic pulmonary arterial pressure (TAPSE/sPAP) ratio were sensitive to treatment initiation. Addition of TAPSE/sPAP ratio to the guideline approach numerically increased its ability to discriminate outcome status. Conclusion Our real-world data suggest that residual risk can be captured by noninvasive clinical procedures during routine follow-up assessments in patients with PAH and highlights the potential use of echocardiographic imaging to refine risk assessment.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
    Hoeper, Marius M.
    Pausch, Christine
    Olsson, Karen M.
    Huscher, Doerte
    Pittrow, David
    Gruenig, Ekkehard
    Staehler, Gerd
    Vizza, Carmine Dario
    Gall, Henning
    Distler, Oliver
    Opitz, Christian
    Gibbs, J. Simon R.
    Delcroix, Marion
    Ghofrani, H. Ardeschir
    Park, Da-Hee
    Ewert, Ralf
    Kaemmerer, Harald
    Kabitz, Hans-Joachim
    Skowasch, Dirk
    Behr, Juergen
    Milger, Katrin
    Halank, Michael
    Wilkens, Heinrike
    Seyfarth, Hans-Juergen
    Held, Matthias
    Dumitrescu, Daniel
    Tsangaris, Iraklis
    Vonk-Noordegraaf, Anton
    Ulrich, Silvia
    Klose, Hans
    Claussen, Martin
    Lange, Tobias J.
    Rosenkranz, Stephan
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60 (01)
  • [42] Prognosis in Hispanic patient population with pulmonary arterial hypertension: An application of common risk stratification models
    Fadah, Kahtan
    Cruz Rodriguez, Jose B.
    Alkhateeb, Haider
    Mukherjee, Debabrata
    Garcia, Hernando
    Schuller, Dan
    Mohammad, Khan O.
    Sahay, Sandeep
    Nickel, Nils P.
    PULMONARY CIRCULATION, 2023, 13 (02)
  • [43] Assessing risk in pulmonary arterial hypertension: what we know, what we don't
    Benza, Raymond L.
    Farber, Harrison W.
    Selej, Mona
    Gomberg-Maitland, Mardi
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (02)
  • [44] Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review
    Lokhorst, Chantal
    van der Werf, Sjoukje
    Berger, Rolf M. F.
    Douwes, Johannes M.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (13):
  • [45] High-level clinical research promotes the development of risk stratification for pulmonary arterial hypertension
    Lu, Dan
    Zhang, Jiexin
    Cheng, Chunyan
    Yang, Yinjian
    Liu, Tengfei
    Zhang, Suxin
    Qiu, Baochen
    Li, Xianmei
    Guo, Fan
    Li, Jingyi
    Xu, Xiqi
    Sun, Kai
    Jing, Zhicheng
    CHINESE SCIENCE BULLETIN-CHINESE, 2024, 69 (13): : 1715 - 1724
  • [46] Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China
    Gong, Su-Gang
    Wu, Wen-Hui
    Li, Chao
    Zhao, Qin-Hua
    Jiang, Rong
    Luo, Ci-Jun
    Qiu, Hong-Ling
    Liu, Jin-Ming
    Wang, Lan
    Zhang, Rui
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [47] The impact of specific pulmonary arterial hypertension therapy on cardiac fluorodeoxyglucose distribution in PET/MRI hybrid imaging-follow-up study
    Kazimierczyk, Remigiusz
    Szumowski, Piotr
    Nekolla, Stephan G. G.
    Malek, Lukasz A. A.
    Blaszczak, Piotr
    Hladunski, Marcin
    Sobkowicz, Bozena
    Mysliwiec, Janusz
    Kaminski, Karol A. A.
    EJNMMI RESEARCH, 2023, 13 (01)
  • [48] Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry Enrollment Characteristics and 1-Year Follow-up
    Kerr, Kim M.
    Elliott, C. Greg
    Chin, Kelly
    Benza, Raymond L.
    Channick, Richard N.
    Davis, R. Duane
    He, Feng
    LaCroix, Andrea
    Madani, Michael M.
    McLaughlin, Vallerie V.
    Park, Myung
    Robbins, Ivan M.
    Tapson, Victor F.
    Terry, Jeffrey R.
    Test, Victor J.
    Jain, Sonia
    Auger, William R.
    CHEST, 2021, 160 (05) : 1822 - 1831
  • [49] Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension
    Simpson, Catherine E.
    Damico, Rachel L.
    Hassoun, Paul M.
    Martin, Lisa J.
    Yang, Jun
    Nies, Melanie K.
    Vaidya, R. Dhananjay
    Brandal, Stephanie
    Pauciulo, Michael W.
    Austin, Eric D.
    Ivy, D. Dunbar
    Nichols, William C.
    Everett, Allen D.
    CHEST, 2020, 157 (06) : 1606 - 1616
  • [50] Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials?
    Sanna, Lilian
    Todea, Andreea
    RESPIRATORY MEDICINE AND RESEARCH, 2022, 81